Both the companies will work together to offer expanded capabilities that build on the core expertise of each business.
Porsolt offers specialized preclinical pharmacology services across many disease areas and physiological systems and processes.
In addition JSW offers full clinical research services from Phase I to Phase IV.
JSW president and CEO Manfred Windisch said this agreement allows them to combine contract research services, proprietary disease models and technologies, drug discovery capabilities, and provide an expanded portfolio of services for the benefit of the pharma, biotech and research communities.